Gesamter Bestand

Zur Kurzanzeige

Should We Use Dialyzable β-Blockers in Hemodialysis?

dc.creatorGeorgianos P.I., Eleftheriadis T., Liakopoulos V.en
dc.date.accessioned2023-01-31T07:40:45Z
dc.date.available2023-01-31T07:40:45Z
dc.date.issued2022
dc.identifier10.1016/j.xkme.2022.100468
dc.identifier.issn25900595
dc.identifier.urihttp://hdl.handle.net/11615/72144
dc.description.abstract[No abstract available]en
dc.language.isoenen
dc.sourceKidney Medicineen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85129493086&doi=10.1016%2fj.xkme.2022.100468&partnerID=40&md5=882945146cc7b7633c1cb99a3b9efce5
dc.subjectantihypertensive agenten
dc.subjectatenololen
dc.subjectbeta adrenergic receptor blocking agenten
dc.subjectbisoprololen
dc.subjectlisinoprilen
dc.subjectblood pressureen
dc.subjectcell deathen
dc.subjectechocardiographyen
dc.subjectEditorialen
dc.subjectheart arresten
dc.subjecthemodialysisen
dc.subjecthumanen
dc.subjecthypotensionen
dc.subjectmortalityen
dc.subjectproportional hazards modelen
dc.subjectretrospective studyen
dc.subjectElsevier Inc.en
dc.titleShould We Use Dialyzable β-Blockers in Hemodialysis?en
dc.typeotheren


Dateien zu dieser Ressource

DateienGrößeFormatAnzeige

Zu diesem Dokument gibt es keine Dateien.

Das Dokument erscheint in:

Zur Kurzanzeige